Mosaic Immunoengineering INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
Mosaic ImmunoEngineering's 10-K filing reveals significant going concern risks due to insufficient working capital and ongoing discussions for a potential acquisition of Oncotelic's technologies, which could lead to substantial dilution.
OTC.Pink
10-K: Mosaic ImmunoEngineering Faces Going Concern Uncertainty Amidst Pursuit of Oncotelic Acquisition
Mosaic ImmunoEngineering's 10-K filing reveals substantial doubt about its ability to continue as a going concern, despite efforts to acquire new technologies from Oncotelic Therapeutics.
OTC.Pink
Mosaic ImmunoEngineering reports a net loss of $1.008 million for 2023 and faces substantial doubt about its ability to continue as a going concern due to insufficient working capital and the termination of a key license agreement.